. Because of this high rate of secondary spread and infection, the American Academy of Pediatrics Committee on Infectious Diseases currently recommends rifampin prophylaxis for close contacts and index patients before their discharge from the hospital (1), when the patients are just completing their treatments with ampicillin or chloramphenicol. There are no data concerning the in vitro interactions of rifampin and ampicillin or rifampin and chloramphenicol. To be certain that there is no adverse antimicrobial interaction from combining these antibiotics, we have assessed their combined in vitro activity against recent H. influenzae type b isolates.
Twenty clinical isolates of Haemophilus influenzae type b were used to determine the in vitro interactions of rifampin with ampicillin or chloramphenicol. Potential interactions of the drugs were evaluated by calculating the fractional inhibitory concentration index and fractional bactericidal concentration index for each strain after treatments with the drugs alone and in combination. There was no evidence of synergy or antagonisms between ampicillin and rifampin or between chloramphenicol and rifampin. With ampicillin-susceptible H. influenzae type b strains, an additive effect was observed with seven strains, and an indifferent effect was observed with three strains. Similarly, with chloramphenicol-susceptible H. influenzae type b strains, an additive effect was observed with eight strains, and an indifferent effect was observed with two strains.
Haemophilus influenzae type b strains are the bacteria responsible for the largest number of serious bacterial infections in infants and young children (2) . Since 1974 there has been an increasing incidence of ampicillin resistance among H. influenzae type b isolates (8, 12, 13) . Therefore, presently, when an infection caused by this bacteria is suspected, treatment with ampicillin and chloramphenicol is initiated.
Studies have demonstrated a propensity of H. influenzae type b to readily spread among the close contacts of patients who have severe H. influenzae type b disease (3, 4, 16) . Because of this high rate of secondary spread and infection, the American Academy of Pediatrics Committee on Infectious Diseases currently recommends rifampin prophylaxis for close contacts and index patients before their discharge from the hospital (1), when the patients are just completing their treatments with ampicillin or chloramphenicol. There are no data concerning the in vitro interactions of rifampin and ampicillin or rifampin and chloramphenicol. To be certain that there is no adverse antimicrobial interaction from combining these antibiotics, we have assessed their combined in vitro activity against recent H. influenzae type b isolates.
MATERIALS AND METHODS
Of the 20 clinical isolates of H. influenzae type b used in this study, 12 were from the Ontario Provincial Health Laboratory, and 8 were from The Hospital for Sick Children. Of these same isolates, 11 were from blood, and 9 were from cerebrospinal fluid. Of the strains, 10 were beta-lactamase negative and ampicillin susceptible, and the other 10 were beta-lactamase positive and ampicillin resistant. These latter strains were all susceptible to chloramphenicol. The isolates from the Provincial Laboratory had been maintained at -70°C in brain heart infusion broth with 10% glycerol. Those from our hospital had been maintained at -70°C in 10% Levinthal broth with 50% glycerol. Antimicrobial susceptibility was determined by a broth microdilution test (10) . MuellerHinton broth was supplemented with 5% lysed, centrifuged, filtered horse blood and 2. cells per ml. The plates were inoculated with an automated dispensing system by using 0.05 ml of each drug and 0.05 ml of the above culture. Concentrations of ampicillin in the plates ranged from 0.025 to 12.8 ,ug/ml, and those of rifampin ranged from 0.06 to 4 p.g/ml. Concentrations of chloramphenicol in the plates ranged from 0.06 to 32 p.g/ml. A row of wells in each plate was kept as a control. In the control row, three wells contained only media, and five wells contained media plus 0.05 ml of the culture. Plates were incubated for 24 h at 37°C, and the MIC was defined as the lowest concentration of antibiotic or combination of antibiotics that inhibited visible growth of the organism.
The MBC was determined by transferring ca. 0.025 ml from each well of the microdilution plate, with an eightprong inoculator, to a Levinthal agar plate. The Levinthal agar plates were incubated at 37°C for 24 h. The MBC was defined as the lowest concentration of antibiotic or combination of antibiotics that prevented growth on subculture.
In evaluating the potential interactions between ampicillin and rifampin and between chloramphenicol and rifampin, we calculated the fractional inhibitory concentration (FIC) index and fractional bactericidal concentration (FBC) index for each strain according to the following formulas (5): FIC = (MIC of drug in combination/MIC of drug alone) and FBC = (MBC of drug in combination/MBC of drug alone).
The FIC index is the sum of the FICs for each drug in the combination. Similarly, the FBC index is the sum of FBCs of each drug in the combination. Synergy was defined as an FIC or FBC index of s0. 5 Tables 1 and 2 . FIC and FBC indices are also indicated. All isolates were susceptible to rifampin at c0.5 pug/ml. The MICs of ampicillin-susceptible organisms ranged from 0.025 to 0.4 ,ug/ml. The MBCs ranged from 0.05 to 0.4 ,ug/ml. As shown in Table 2 , the MICs of chloramphenicol-susceptible isolates ranged from 0.5 to 1 ,ug/ml, and the MBCs ranged from 1 to 2 ,ug/ml.
There was no evidence of synergy or antagonism between ampicillin and rifampin against the ampicillin-susceptible strains of H. infliuenzae type b. An additive effect was observed with seven strains, and an indifferent effect was observed with three strains. Similarly, there was no synergy or antagonism between rifampin and chloramphenicol against the chloramphenicol-susceptible strains of H. infliuenzae type b. An additive effect was observed with eight strains, and an indifferent effect was observed with two strains.
DISCUSSION
In this study we tested the in vitro interaction of rifampin with either ampicillin or chloramphenicol. We found that there was no synergistic or antagonistic effect between rifampin and either ampicillin or chloramphenicol.
Combinations of rifampin and penicillins against grampositive cocci have frequently been observed to be antagonistic in vitro (15 (14) noted synergy against some S. aureus strains with rifampin and nafcillin, partial synergy, indifference, or antagonism was observed with most strains. Antagonism between penicillin and rifampin has also been demonstrated against a majority of strains of group B streptococci (9) . Although there was no evidence in our study of antagonism between rifampin and either ampicillin or chloramphenicol, there is another potential problem with using these agents together. Rifampin is an inducer of hepatic enzymes responsible for the metabolism of certain drugs such as chloramphenicol (6) . It is conceivable that chloramphenicol serum and, hence, cerebrospinal fluid concentrations might be reduced by the concomitant adminstration of rifampin. This has been described with another inducer of hepatic metabolism, phenobarbital (7) . We are presently investigating this potential interaction of rifampin and chloramphenicol.
